Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Bank of America

Here are the best dividend picks in Berkshire Hathaway's portfolio.

3 Warren Buffett Dividend Stocks to Buy in February

Atmos Energy

Altria

Novartis

Northwest Natural Gas

Reckitt Benckiser Group PLC

RenaissanceRe Hlds

Unilever

Verizon

Volatility is back on Wall Street, with tech suffering its worst month since 2008. No one knows how long or deep the 2022 correction will be, but prudent risk-management, not market timing is your best option for protecting your retirement nest egg.

10 High-Yield Sleep Well At Night Blue-Chips Perfect For This Correction

Dividend stocks to watch as markets continue to be choppy.

Best Dividend Stocks To Buy Now? 3 For Your List

Apple

Boeing

Microsoft

Netflix

To say it was a volatile week on Wall Street would be an understatement.

Dramatic Afternoon Trading Highlights Tumultuous Week on Wall Street

Amazon

Salesforce

Alphabet

Home Depot

Coca-Cola

NVIDIA

Realty Income Corp

PepsiCo

These ten stocks are a great foundation for investors dealing with this market correction.

Start Your Investing Resolutions Off Right With This Classic Stock Bundle

NEW BRUNSWICK, N.J., Jan. 27, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23 rd, Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m.

Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference

Johnson & Johnson ( JNJ , Financial) is on the lookout for medical device and biotech companies to add to the fold, but in the case of the latter, it might be beaten to the punch by a pair of Big Pharma rivals. One could be Novartis ( NVS , Financial), which recently sold its ownership in Roche ( RHHBY , Financial) and could add to its coffers if it divests the Sandoz generics unit, according to a BioPharma Dive article.

Johnson & Johnson Hunting for Biotech, Medical Device Acquisitions

The comments made by a Johnson & Johnson JNJ, +1.62% executive earlier this week about biotechnology valuations calls attention to the struggling biotech sector.

J&J exec says biotechs aren't ‘necessarily on sale' even after a challenging 2021

Annaly Capital

This stock trio can help you successfully navigate heightened market volatility.

3 of the Safest Stocks to Buy if There's a Stock Market Crash

The S&P 500 may be overdue for a pullback this year.

2 Charts That Show Why Investors Might Be More Conservative in 2022

Johnson & Johnson (NYSE: JNJ) shares are moving higher on a mixed report. The company missed on the top line but margins came in well above expectation and drove solid results on the bottom line.

Is It Time To Buy The Rebound In Johnson & Johnson?

Johnson & Johnson, the world's largest health care products company, reported that sales of its Covid vaccine have accelerated, but they'll still lag far behind other vaccines for the foreseeable future.

Johnson & Johnson expects its Covid vaccine sales to surge -- but still lag its rivals

Moving to split its consumer health and medical device/pharma units into two separate public companies, the Johnson & Johnson (JNJ) version of “divide and conquer” revolves around increased ability to funnel research and investment into these new centers of excellence. Incoming CEO Joaquin Duato said separation of the consumer health, pharmaceutical and medical device businesses […]

Johnson & Johnson Readies to Spin Off Business Units As COVID Effects Linger in 2022

Johnson & Johnson (JNJ) CEO Joaquin Duato on Q4 2021 Results - Earnings Call Transcript

J&J (JNJ) reports mixed fourth-quarter results. It beats estimates for earnings but misses the same for sales.

J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss

General Electric

The Dow is -250 points at the hour, while the Nasdaq is down -260; the S&P 500 has dropped -60 points from yesterday's close.

Market Selling Resumes; GE, J&J Miss on Revenues

Johnson & Johnson (NYSE:JNJ) is struggling for direction today, last seen up 0.3% to trade at $162.88, after the blue-chip concern posted slightly better-than-expected fourth-quarter earnings.

Options Traders Eye Blue-Chip Stock After Earnings

Johnson & Johnson (NYSE: JNJ) on Tuesday reported lower-than-expected revenue for its fiscal fourth quarter. Shares still jumped 2.5% this morning on strong guidance for the future.

J&J CFO on Q4 results: ‘we're very well positioned for 2022'

We're checking in on some of the top stocks to watch Tuesday as several major companies release Q4 earnings reports today! The post Stocks to Watch Tuesday: What's Moving VZ, JNJ, GE, IBM and MMM Today appeared first on InvestorPlace.

Stocks to Watch Tuesday: What's Moving VZ, JNJ, GE, IBM and MMM Today

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.47% and 1.77%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates

Investors were initially unenthused with the report, sending shares of J&J down 1.7% in premarket trading.

J&J's Earnings Were Mixed. Why the Stock Is Falling.

J&J expects its Covid vaccine to generate $3 billion to $3.5 billion in sales this year.

J&J expects more than $3 billion in Covid vaccine sales this year in mixed quarterly report

Johnson & Johnson (NYSE: JNJ) has reported Q4 adjusted earnings of $2.13 per share, up 14.5% Y/Y over the $1.86 posted a year ago and marginally ahead of the consensus of $2.12. Net sales increased 10.4% Y/Y to $24.8 billion, missing the consensus of $25.29 billion.

Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson shares slid 1.3% premarket Tuesday, after the consumer goods, pharmaceutical and medical device maker posted weaker-than-expected revenue for the fourth quarter. The company posted net income of $4.736 billion, or $1.77 a share, for the quarter, up from $1.738 billion, or 65 cents a share, in the year-earlier period.

J&J shares down 1.3% premarket after Q4 revenue lags consensus

Johnson & Johnson on Tuesday forecast $3 billion-$3.5 billion in revenue for its COVID-19 vaccine this year, more than the $2.39 billion it generated in 2021 even as the drugmaker faces manufacturing issues and uneven demand.

News for Johnson & Johnson Stock (JNJ)